Premium
P2‐437: Modem: A Comprehensive Approach to Modelling Outcome and Cost Impacts of Interventions For Dementia
Author(s) -
Comas-Herrera Adelina,
John Knapp Martin Richard
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1649
Subject(s) - dementia , psychological intervention , health care , cost–benefit analysis , gerontology , quality of life (healthcare) , medicine , business , psychology , disease , nursing , economics , economic growth , political science , pathology , law
Background:The MODEM project (A comprehensive approach to MODelling outcome and costs impacts of interventions for DEMentia) explores how changes in arrangements for the future treatment and care of people with dementia, and support for family carers, could result in better outcomes and more efficient use of resources. Methods: The MODEM team has conducted a systematic mapping of the literature on effective and (potentially) cost-effective interventions in dementia care. We are using those findings to model the quality of life and cost impacts of making these interventions more widely available in England over the period from now to 2040. We are using a suite of models, combining micro and macrosimulationmethods, modelling the costs and outcomes of care, both for an individual over the lifecourse and for individuals and the country as whole in a particular year. The MODEM project concludes in 2018; we present intermediate outcomes from the evidence review and the lifecourse model. Results: Current costs of dementia in the UK are around £21 billion, but those costs could change with wider availability of cost-effective care and support. If medications to alleviate the symptoms of dementia were available to everyone with Alzheimer’s disease, savings could be c.£250 million in overall costs, comprising a saving of c.£400 million in social care with a partially offsetting extra cost of £150 million for unpaid care. If cognitive stimulation therapy was delivered to everyonewith mild/moderate dementia, therewould be little difference in overall costs, with a slight shift from social care to health care costs. Finally, if family caregivers of people with dementia were supported with the START coping intervention, overall costs could be c.£200 million higher than they are today, comprising savings of £200 million on health and social care and an extra £400 million in unpaid caregiver costs. There would however be significant improvements in caregiver quality of life. Conclusions: Making cost-effective interventions more widely available has the potential to reduce costs of care and improve the quality of life both of people with dementia and their family caregivers.